Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet)
Reference Brands: Viekira Pak® (US); Viekirax® + Exviera® (EU)
Category:
Hepatitis
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir, marketed as Viekira Pak® (US) and Viekirax® + Exviera® (EU), is a fixed-dose oral combination for Hepatitis C genotype 1. Approved by FDA and EMA, it offers an effective interferon-free treatment option, often used with ribavirin in B2B supply for global pharmaceutical markets.
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is available in Tablet
and strengths such as Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is a fixed-dose combination therapy used in the treatment of chronic Hepatitis C genotype 1. Marketed as Viekira Pak® in the US and Viekirax® + Exviera® in the EU, this regimen includes four direct-acting antivirals that target multiple stages of the HCV replication cycle. It offers a non-interferon-based treatment, often in combination with ribavirin. EMA and FDA approved, it’s a key option for B2B pharmaceutical partners sourcing branded and generic HCV therapies. Suitable for hospital, retail, and tender supply in regulated and semi-regulated markets. Available in tablet form with clearly defined daily dosing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing